Reimbursement Environment Deteriorates For Drugmakers & Patients

BMI believes Lithuania's pricing and reimbursement environment is becoming increasingly negative for major pharmaceutical companies and patients. A Government of the Republic of Lithuania Decree has introduced two mechanisms through which it aims to reduce state expenditure on medicines: the use of therapeutics reference pricing; and the addition of Bulgaria and Romania to its reference pricing scheme. BMI believes these changes will most heavily affect manufacturers of originator and high-priced branded generics (including originator

To read the full article, please choose one of the following options: